Treprostinil benefits PAH patients with cardiovascular issues

PHA Canada
Feb 4
1 min read

Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new analysis of data from two clinical trials indicated that treprostinil (Remodulin) in addition to existing treatment was safe and effective in preventing clinical worsening for these patients.

Read the CHEST journal article here

Recent Posts

See All

Some PH patients with interstitial lung disease may benefit from oral PAH drugs

Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to...

ZENITH results published: sotatercept is effective for high-risk PAH patients

The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...

Main pulmonary artery diameter predicts risk in PAH patients

Researchers wanted to know whether an enlarged pulmonary artery could independently predict risk in pulmonary arterial hypertension (in...

Comments